Citations (49)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Olufemi O. Oyewole, Adetola C. Adebayo, Taofeek O. Awotidebe, Chidozie E. Mbada, Clara Fatoye, Blessing S. Ige, Tadesse Gebrye & Francis Fatoye. (2022) Willingness-to-pay for physiotherapy services and its determinant among Nigerian stroke survivors. Physical Therapy Reviews 27:5, pages 376-383.
Read now
Read now
Mette Bøgelund, Lise Hagelund & Mikael Bergholdt Asmussen. (2017) COPD-treating nurses’ preferences for inhaler attributes – a discrete choice experiment. Current Medical Research and Opinion 33:1, pages 71-75.
Read now
Read now
Katie D Stewart, Joseph A Johnston, Louis S Matza, Sarah E Curtis, Henry A Havel, Stephanie A Sweetana & Heather L Gelhorn. (2016) Preference for pharmaceutical formulation and treatment process attributes. Patient Preference and Adherence 10, pages 1385-1399.
Read now
Read now
Sara Olofsson, Hanna Norrlid & Ulf Persson. (2016) Preferences for improvements in attributes associated with basal insulin: a time trade-off and willingness-to-pay survey of a diabetic and non-diabetic population in Sweden. Journal of Medical Economics 19:10, pages 945-958.
Read now
Read now
Carlos Morillas, Rosa Feliciano, Pablo Fernández Catalina, Carla Ponte, Marta Botella, João Rodrigues, Enric Esmatjes, Javier Lafita, Luis Lizán, Ignacio Llorente, Cristóbal Morales, Jorge Navarro-Pérez, Domingo Orozco-Beltran, Silvia Paz, Antonio Ramirez de Arellano, Cristina Cardoso & Maribel Tribaldos Causadias. (2015) Patients’ and physicians’ preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experiment. Patient Preference and Adherence 9, pages 1443-1458.
Read now
Read now
George S Panagoulias & John Doupis. (2014) Clinical utility in the treatment of type 2 diabetes with the saxagliptin/metformin fixed combination. Patient Preference and Adherence 8, pages 227-236.
Read now
Read now
Martin Ridderstråle, Marie Markert Jensen, Rasmus Prior Gjesing & Leo Niskanen. (2013) Cost-effectiveness of insulin detemir compared with NPH insulin in people with type 2 diabetes in Denmark, Finland, Norway, and Sweden. Journal of Medical Economics 16:4, pages 468-478.
Read now
Read now
J. Jendle, O. Torffvit, M. Ridderstråle, Å. Ericsson, B. Nilsen & M. Bøgelund. (2012) Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results. Journal of Medical Economics 15:sup2, pages 1-5.
Read now
Read now
J. Jendle, M. Ridderstråle, O. Torfvitt, Å Ericsson & S. Larsen. (2012) Willingness-to-pay for benefits associated with basal insulin treatment of type 2 diabetes. Journal of Medical Economics 15:2, pages 261-263.
Read now
Read now
Mette Bøgelund, Tina Vilsbøll, Jens Faber, Jan Erik Henriksen, Rasmus Prior Gjesing & Morten Lammert. (2011) Patient preferences for diabetes management among people with type 2 diabetes in Denmark – a discrete choice experiment. Current Medical Research and Opinion 27:11, pages 2175-2183.
Read now
Read now
Marco daCosta DiBonaventura, Jan-Samuel Wagner, Cynthia J Girman, Kimberly Brodovicz, Qiaoyi Zhang, Ying Qiu, Sri-Ram Pentakota & Larry Radican. (2010) Multinational Internet-based survey of patient preference for newer oral or injectable Type 2 diabetes medication. Patient Preference and Adherence 4, pages 397-406.
Read now
Read now
Articles from other publishers (38)
Melanie Büssgen & Tom Stargardt. (2023) 10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?. Applied Health Economics and Health Policy 21:5, pages 751-759.
Crossref
Crossref
Jay H. Shubrook, Michael Radin, Sarah N. Ali, Barrie Chubb, Kristina DiPietrantonio, Hannah Collings, Robin Wyn & Martina Smith. (2022) Preference for Type 2 Diabetes Therapies in the United States: A Discrete Choice Experiment. Advances in Therapy 39:9, pages 4114-4130.
Crossref
Crossref
Yuankai Huang, Qixiang Huang, Ailin Xu, Mengqing Lu & Xiaoyu Xi. (2022) Patient Preferences for Diabetes Treatment Among People With Type 2 Diabetes Mellitus in China: A Discrete Choice Experiment. Frontiers in Public Health 9.
Crossref
Crossref
Louis S. Matza, Katelyn N. Cutts, Katie D. Stewart, Kirsi Norrbacka, Luis-Emilio García-Pérez & Kristina S. Boye. (2021) Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes. Quality of Life Research 30:7, pages 2033-2043.
Crossref
Crossref
Laura Canals-Ruiz, Marta Comellas & Luís Lizán. (2021) Preferences, satisfaction and decision-making processes in osteoporosis treatment: a systematic review of the literature. Journal of Comparative Effectiveness Research 10:8, pages 629-645.
Crossref
Crossref
Jana Sommer, Jan Dyczmons, Sandra Grobosch, Veronika Gontscharuk, Markus Vomhof, Michael Roden & Andrea Icks. (2020) Preferences of people with type 2 diabetes for telemedical lifestyle programmes in Germany: protocol of a discrete choice experiment. BMJ Open 10:9, pages e036995.
Crossref
Crossref
Semra Ozdemir, Drishti Baid, Naina R. Verghese, Amanda YR. Lam, Phong Ching Lee, Adoree YY. Lim, Ling Zhu, Sonali Ganguly, Eric A. Finkelstein & Su-Yen Goh. (2020) Patient Preferences for Medications in Managing Type 2 Diabetes Mellitus: A Discrete Choice Experiment. Value in Health 23:7, pages 842-850.
Crossref
Crossref
Ye-Seul Lee, Deuk Su Park, Jae Keun Oh & Song-Yi Kim. (2020) Sports injury type and psychological factors affect treatment period and willingness-to-pay. Medicine 99:50, pages e23647.
Crossref
Crossref
Mahdi Toroski, Abbas Kebriaeezadeh, Alireza Esteghamati, Ali Kazemi Karyani, Hadi Abbasian & Shekoufeh Nikfar. (2019) Patient and physician preferences for type 2 diabetes medications: a systematic review. Journal of Diabetes & Metabolic Disorders 18:2, pages 643-656.
Crossref
Crossref
Johan Jendle, Andreas L. Birkenfeld, William H. Polonsky, Robert Silver, Kari Uusinarkaus, Thomas Hansen, Jonas Håkan‐Bloch, Sayeh Tadayon & Melanie J. Davies. (2019) Improved treatment satisfaction in patients with type 2 diabetes treated with once‐weekly semaglutide in the SUSTAIN trials. Diabetes, Obesity and Metabolism 21:10, pages 2315-2326.
Crossref
Crossref
Christin Juhnke & Axel C. Mühlbacher. (2019) Patientenpräferenzen: Wünsche von Betroffenen mit Diabetes mellitusPatient preferences: what do diabetes patients want?. Der Diabetologe 15:6, pages 534-541.
Crossref
Crossref
Tina Vilsbøll, Ella Ekholm, Eva Johnsson, Nalina Dronamraju, Serge Jabbour & Marcus Lind. (2019) Dapagliflozin Plus Saxagliptin Add-on Therapy Compared With Insulin in Patients With Type 2 Diabetes Poorly Controlled by Metformin With or Without Sulfonylurea Therapy: A Randomized Clinical Trial. Diabetes Care 42:8, pages 1464-1472.
Crossref
Crossref
M. Y. L. Siaw, D. C. Malone, Y. Ko & J. Y.-C. Lee. (2018) Cost-effectiveness of multidisciplinary collaborative care versus usual care in the management of high-risk patients with diabetes in Singapore: Short-term results from a randomized controlled trial. Journal of Clinical Pharmacy and Therapeutics 43:6, pages 775-783.
Crossref
Crossref
Åsa Ericsson, Divina Glah, Maria Lorenzi, Jeroen P. Jansen & Adam Fridhammar. (2018) Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes. PLOS ONE 13:2, pages e0191953.
Crossref
Crossref
Ellen M. Janssen, A. Brett Hauber & John F.P. Bridges. (2018) Conducting a Discrete-Choice Experiment Study Following Recommendations for Good Research Practices: An Application for Eliciting Patient Preferences for Diabetes Treatments. Value in Health 21:1, pages 59-68.
Crossref
Crossref
M. A. Nexo, B. Cleal, Lise Hagelund, I. Willaing & K. Olesen. (2017) Willingness to pay for flexible working conditions of people with type 2 diabetes: discrete choice experiments. BMC Public Health 17:1.
Crossref
Crossref
Anna Rydén, Stephanie Chen, Emuella Flood, Beverly Romero & Susan Grandy. (2017) Discrete Choice Experiment Attribute Selection Using a Multinational Interview Study: Treatment Features Important to Patients with Type 2 Diabetes Mellitus. The Patient - Patient-Centered Outcomes Research 10:4, pages 475-487.
Crossref
Crossref
Lill-Brith von Arx, F. Reed Johnson, Morten Raun Mørkbak & Trine Kjær. (2017) Be Careful What You Ask For: Effects of Benefit Descriptions on Diabetes Patients’ Benefit-Risk Tradeoff Preferences. Value in Health 20:4, pages 670-678.
Crossref
Crossref
Ellen M. Janssen, Jodi B. Segal & John F. P. Bridges. (2016) A Framework for Instrument Development of a Choice Experiment: An Application to Type 2 Diabetes. The Patient - Patient-Centered Outcomes Research 9:5, pages 465-479.
Crossref
Crossref
Narayan Rajan, Kristina S. Boye, Meaghan Gibbs, Yoon Ji Lee, Peter Davey, Mark Ball & Steve M. Babineaux. (2016) Utilities for Type 2 Diabetes Treatment-Related Attributes in a South Korean and Taiwanese Population. Value in Health Regional Issues 9, pages 67-71.
Crossref
Crossref
Inger M. Janssen, Ansgar Gerhardus, Milly A. Schröer-Günther & Fülöp Scheibler. (2015) A descriptive review on methods to prioritize outcomes in a health care context. Health Expectations 18:6, pages 1873-1893.
Crossref
Crossref
Tsung-Tai Chen, Tao-Hsin Tung, Ya-Seng (Arthur) Hsueh, Ming-Han Tsai, Hsiu-Mei Liang, Kay-Lun Li, Kuo-Piao Chung & Chao-Hsiun Tang. (2015) Measuring Preferences for a Diabetes Pay-for-Performance for Patient (P4P4P) Program using a Discrete Choice Experiment. Value in Health 18:5, pages 578-586.
Crossref
Crossref
Axel C. Mühlbacher & A. Kaczynski. (2015) Patientenpräferenzen in der medikamentösen Therapie von Diabetes Mellitus Typ 2Patients’ preferences in the medicamentous treatment of diabetes mellitus type 2. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 58:4-5, pages 452-466.
Crossref
Crossref
Lill-Brith von Arx & Trine Kjær. (2014) The Patient Perspective of Diabetes Care: A Systematic Review of Stated Preference Research. The Patient - Patient-Centered Outcomes Research 7:3, pages 283-300.
Crossref
Crossref
Tanjala S. Purnell, Susan Joy, Emily Little, John F.P. Bridges & Nisa Maruthur. (2014) Patient Preferences for Noninsulin Diabetes Medications: A Systematic Review. Diabetes Care 37:7, pages 2055-2062.
Crossref
Crossref
S. Glogner, A. Rosengren, M. Olsson, S. Gudbjörnsdottir, A.-M. Svensson & M. Lind. (2014) The association between BMI and hospitalization for heart failure in 83 021 persons with Type 2 diabetes: a population-based study from the Swedish National Diabetes Registry. Diabetic Medicine 31:5, pages 586-594.
Crossref
Crossref
Pedro Mezquita Raya & Rebeca Reyes García. (2014) ¿Es eficiente el tratamiento con liraglutida?. Endocrinología y Nutrición 61:4, pages 202-208.
Crossref
Crossref
Pedro Mezquita Raya & Rebeca Reyes García. (2014) Is treatment with liraglutide efficient?. Endocrinología y Nutrición (English Edition) 61:4, pages 202-208.
Crossref
Crossref
Jorien Veldwijk, Mattijs S Lambooij, Paul F van Gils, Jeroen N Struijs, Henriëtte A Smit & G Ardine de Wit. (2013) Type 2 diabetes patients’ preferences and willingness to pay for lifestyle programs: a discrete choice experiment. BMC Public Health 13:1.
Crossref
Crossref
A.F. Mohamed, J. Zhang, F.R. Johnson, I. Duprat Lomon, E. Malvolti, R. Townsend, C.J. Östgren & K.G. Parhofer. (2013) Avoidance of weight gain is important for oral type 2 diabetes treatments in Sweden and Germany: Patient preferences. Diabetes & Metabolism 39:5, pages 397-403.
Crossref
Crossref
Michèle Sennhauser & Peter Zweifel. (2014) Ist ein neues Arzneimittel sein Geld wert? Wessen Geld? – Bewertung eines neuen Diabetes-Präparats mit Hilfe eines Discrete-Choice-Experiments. PharmacoEconomics German Research Articles 11:2, pages 45-63.
Crossref
Crossref
Susan M. Joy, Emily Little, Nisa M. Maruthur, Tanjala S. Purnell & John F. P. Bridges. (2013) Patient Preferences for the Treatment of Type 2 Diabetes: A Scoping Review. PharmacoEconomics 31:10, pages 877-892.
Crossref
Crossref
H. L. Gelhorn, S. M. Stringer, A. Brooks, C. Thompson, B. U. Monz, K. S. Boye, T. Hach, S. S. Lund & R. Palencia. (2013) Preferences for medication attributes among patients with type 2 diabetes mellitus in the UK. Diabetes, Obesity and Metabolism 15:9, pages 802-809.
Crossref
Crossref
Zachary T. Bloomgarden, Lawrence Blonde, Alan J. Garber & Carol H. Wysham. (2012) Current Issues in Glp-1 Receptor Agonist Therapy for Type 2 Diabetes. Endocrine Practice 18, pages 6-26.
Crossref
Crossref
Michaela Schiøtz, Mette Bøgelund, Thomas Almdal & Ingrid Willaing. (2012) Discrete choice as a method for exploring education preferences in a Danish population of patients with type 2 diabetes. Patient Education and Counseling 87:2, pages 217-225.
Crossref
Crossref
Marcus Lind, Johan Jendle, Ole Torffvit & Ibe Lager. (2012) Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction. Primary Care Diabetes 6:1, pages 41-46.
Crossref
Crossref
Javier Soto ÁlvarezJavier Soto Álvarez. 2012. Evaluación económica de medicamentos y tecnologías sanitarias:. Evaluación económica de medicamentos y tecnologías sanitarias:
85
92
.
Won Chan Lee, Christopher Conner & Mette Hammer. (2010) Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States. Clinical Therapeutics 32:10, pages 1756-1767.
Crossref
Crossref